Medscape Oncology
By Medscape
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
Podcast Description
Latest medical news and features from Medscape Oncology
| Name | Description | Released | Price | ||
|---|---|---|---|---|---|
|
1 |
Lung Cancer: New Drugs, Emerging Therapies | Dr. Mark Kris highlights new developments in lung cancer -- including targeted therapies for small cell carcinoma and promising immunotherapies -- to be presented at ASCO® 2012. | 5/24/12 | Free | View In iTunes |
|
2 |
GI Cancers: Promising Data Across the Board | Dr. David Kerr previews what he expects are practice-changing studies in colorectal, gastric, esophageal, and hepatocellular cancer, to be presented at ASCO® 2012. | 5/24/12 | Free | View In iTunes |
|
3 |
Colorectal Cancer: New Drugs, Emerging Paradigms | Dr. John Marshall highlights colorectal studies on aflibercept, regorafenib, maintenance therapy, perioperative chemotherapy, and second-line therapy, to be presented at ASCO® 2012. | 5/21/12 | Free | View In iTunes |
|
4 |
Plenary Session: 4 Critical Advances in Oncology | Dr. Kathy Miller previews the ASCO plenary session studies in breast cancer, prostate cancer, lymphoma, and oligodendroglioma, all 4 of which signal significant advances in science and treatment. | 5/17/12 | Free | View In iTunes |
|
5 |
Should HIFU Be Presented as 'Experimental'? | A new study provides interesting data on HIFU for prostate cancer, but there are still not enough data to recommend HIFU beyond offering it as an 'experimental therapy', says Dr. Gerald Chodak. | 5/15/12 | Free | View In iTunes |
|
6 |
Crossing Boundaries in Molecular Therapy: HER2 in ALL | Looking at a recent report describing the use of trastuzumab in HER2-positive ALL, Dr. Maurie Markman considers what this means for the future of molecular-targeted cancer therapy. | 5/15/12 | Free | View In iTunes |
|
7 |
Endometrial Cancer: Drop the Doxorubicin | Dr. Maurie Markman reports on a phase 3 trial confirming that paclitaxel-carboplatin is equivalent and less toxic than paclitaxel-carboplatin-doxorubicin in metastatic endometrial cancer. | 5/11/12 | Free | View In iTunes |
|
8 |
Can a Hospital Say, 'Only Thin Doctors Can Work Here'? | A Texas hospital refuses to hire overweight staff, including doctors and nurses. Is this ethical -- or sensible? A leading bioethicist gives his take on the situation. | 5/3/12 | Free | View In iTunes |
|
9 |
Does Inflammation Stoke Cancer Growth? | Investigations into the microenvironment of tumor cells suggest that aspects of inflammation promote tumor growth. But Dr. David Kerr finds a gap in our understanding of good and bad inflammation. | 4/19/12 | Free | View In iTunes |
|
10 |
Topol on The Creative Destruction of Medicine | The biggest shake-up in the history of medicine is coming and most doctors aren't ready. Dr. Eric Topol tells Dr. John Reed how physicians can prepare. | 4/13/12 | Free | View In iTunes |
|
11 |
Early Reports on T-DM1 Breast Cancer Trial | Dr. Kathy Miller comments on early reports that a phase 3 trial of T-DM1 shows "substantially" increased survival in HER2-positive breast cancer patients. | 4/13/12 | Free | View In iTunes |
|
12 |
Does Elevated Risk Require MRI? | Dr. Kathy Miller commends the American College of Radiology Imaging Network (ACRIN) for a recent study assessing the value of MRI in women at intermediate risk for breast cancer. | 4/6/12 | Free | View In iTunes |
|
13 |
Cleaning the Healthcare Closet | Because the healthcare budget is not likely to get any bigger, Dr. John Marshall comments that we may need to 'clean the healthcare closet' to make room for new therapies. What can we do without? | 3/29/12 | Free | View In iTunes |
|
14 |
Circumcision Hype? | A new study linking circumcision before sexual i*********e to lower rates of prostate cancer may be so flawed that the conclusions are meaningless, says Dr. Gerald Chodak. | 3/28/12 | Free | View In iTunes |
|
15 |
Emerging Problem in ALK-Positive Lung Cancer | Dr. Mark Kris addresses the emerging clinical problem of how to treat patients with ALK-positive NSCLC whose disease progresses on crizotinib. | 3/26/12 | Free | View In iTunes |
|
16 |
Steve Jobs: One More Thing | Dr. Bruce Cheson comments on Walter Isaacson's biography Steve Jobs, finding a poignant lesson in the life and death of the entrepreneur whom the author calls a 'magician genius.' | 3/23/12 | Free | View In iTunes |
|
17 |
CTC Count: Liquid Biopsy? | Kerr reports on the largest prospective study showing the significant prognostic value of circulating tumor cells in breast cancer, and suggests manipulation of CTCs as a liquid biopsy is not far off. | 3/19/12 | Free | View In iTunes |
|
18 |
How We Do Harm | Dr. Kathy Miller provides a short book review of Dr. Otis Brawley and Paul Goldberg's essential review of the US healthcare system. | 3/13/12 | Free | View In iTunes |
|
19 |
Star Wars in the Empire of All Maladies | Dr. Bruce Cheson and his fellows discuss The Emperor of All Maladies, Siddhartha Mukherjee’s book about the history of cancer, and pick the investigators whose contributions they find most compelling. | 3/2/12 | Free | View In iTunes |
|
20 |
REDEEM: How Useful Is Dutasteride in Low-Risk Prostate Cancer? | A new study published in The Lancet found that dutasteride may be helpful during active surveillance of men with low-risk prostate cancer, but there are some limitations. Dr. Gerald Chodak discusses. | 2/27/12 | Free | View In iTunes |
|
21 |
Can Aspirin Slow Cancer Progression? | Dr. David Kerr reports on a study detailing the link between inflammation and colorectal carcinogenesis and how it might be exploited to slow tumor progression and possibly even prevent CRC. | 2/21/12 | Free | View In iTunes |
|
22 |
Exercise: A Way to Outdistance Breast Cancer? | Dr. Kathy Miller reports on a study that shows that exercise can lessen the risk for breast cancer in sedentary postmenopausal women. Can exercise also improve breast cancer prognosis? | 2/17/12 | Free | View In iTunes |
|
23 |
Do Unpublished Data Need an Expiration Date? | Dr. Bruce Cheson says that study data can be updated for years at meetings before the results are published. Should there be a limit to such updating to prevent premature data from dying on the vine? | 2/15/12 | Free | View In iTunes |
|
24 |
Proton Therapy for Prostate Cancer: Benefits Overblown? | A society for radiation oncologists touts new studies on the benefits of proton radiation therapy in prostate cancer, but is the evidence really solid? Dr. Gerald Chodak discusses the issue. | 2/8/12 | Free | View In iTunes |
|
25 |
EMR: Efficiency Mauled Repeatedly | Dr. John Marshall says that his efficiency as a clinician is undermined as he spends more and more time entering data into the EMR with less and less administrative support. Is there a way out? | 2/3/12 | Free | View In iTunes |
|
26 |
Lung Tumor Grows, but Must Chemo Change? | Dr. Mark Kris discusses cancer progression, as defined by RECIST criteria, and the situations in which increased tumor size in NSCLC need not prompt a change in standard chemotherapy. | 2/3/12 | Free | View In iTunes |
|
27 |
Bevacizumab: Important Drug for NSCLC | Dr. Mark Kris highlights the therapeutic benefits -- and toxicities -- associated with bevacizumab use in patients with non-small cell lung cancer. | 1/30/12 | Free | View In iTunes |
|
28 |
Is HIFU Ever a 'Reasonable' Option in Prostate Cancer? | Disappointing study results raise questions about the efficacy and safety of high-intensity focused ultrasound (HIFU) in localized, recurring prostate cancer, says Dr. Gerald Chodak. | 1/30/12 | Free | View In iTunes |
|
29 |
Healthcare Gone Missing: The State of the Union Address | Henry R. Black, MD, and Roxana Mehran, MD, talked with Medscape after the 2012 State of the Union address about why healthcare was missing and what that portends. | 1/26/12 | Free | View In iTunes |
|
30 |
After 13 Years, Still No Clear Benefit From PSA Screening | Dr. Gerald Chodak reviews the latest analysis of data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, including criticisms of contamination. | 1/20/12 | Free | View In iTunes |
|
31 |
HPV and the Increased Incidence of Oropharyngeal Cancer | Dr. Maurie Markman reports on a study indicating that increased incidence of oropharyngeal cancer can be attributed to increased prevalence of HPV infection, underscoring the need for HPV vaccination. | 1/20/12 | Free | View In iTunes |
|
32 |
Radioimmunotherapy: How Strong an Option Is It? | Dr. Bruce Cheson reviews recent and older studies to assess how strong a treatment option radioimmunotherapy is for patients with follicular lymphoma. | 1/20/12 | Free | View In iTunes |
|
33 |
Drug Shortages: A Problem for Everyone | Drug shortages occur in all disease states and affect all populations. Dr. Maris discusses this serious and growing issue. | 1/20/12 | Free | View In iTunes |
|
34 |
Reason to RESORT to Rituximab Maintenance? | Dr. Bruce Cheson reviews the RESORT study, which addresses the controversial issue of rituximab maintenance therapy in patients with follicular lymphoma. | 1/17/12 | Free | View In iTunes |
|
35 |
HRSA's Wakefield on CHCs, ACOs and Strengthening the Health Workforce | Community health centers may already be ahead of the curve when it comes to care coordination, strengthening the healthcare workforce and the implementation of ACOs under the Affordable Care Act. | 1/10/12 | Free | View In iTunes |
|
36 |
Clinical Trial Woes: Where Are the Drugs? | Dr. Bruce Cheson describes the bureaucratic complications and glacial pace of clinical trials in the United States as they relate to lymphoma research. | 1/9/12 | Free | View In iTunes |
|
37 |
HER2-Positive Breast Cancer and Long Life | Dr. Kathy Miller takes another look at CLEOPATRA and predicts that dual HER2 blockade, when offered in the adjuvant setting, will make HER2+ breast cancer a disease patients can live with, for years. | 1/9/12 | Free | View In iTunes |
|
38 |
A Personalized Approach to Cancer Care | Has the time arrived for a personalized approach to cancer care for both children and adults? | 1/3/12 | Free | View In iTunes |
|
39 |
Great New Drugs Will Be Harder to Come By | Dr. Bruce Cheson discusses the Cheson Rule for New Drug Approval, which states (rather paradoxically) that the more effective a drug is, the more it negatively affects future drug development. | 12/29/11 | Free | View In iTunes |
|
40 |
Has Rituximab Met Its Match in Lymphoma? | Drs. Bruce Cheson and John Leonard review the highlights of ASH 2011. | 12/27/11 | Free | View In iTunes |
|
41 |
Two New Winners for CML? | The drugs keep coming -- and the results remain impressive -- for treatment of chronic myeloid leukemia. | 12/23/11 | Free | View In iTunes |
|
42 |
HPV Vaccination: Can It Prevent CIN3 and AIS? | Dr. Maurie Markman reports a trial of 10,000 young women that assesses the effectiveness of HPV vaccination in the prevention of cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ. | 12/20/11 | Free | View In iTunes |
|
43 |
SABCS: Winning and Also-Ran Results | Drs. Kathy Miller and George Sledge review the hits and misses in breast cancer research from SABCS 2011. | 12/19/11 | Free | View In iTunes |
|
44 |
The Consequences of Stopping Targeted Therapy | Cancer patients who stop targeted therapy often show a rapid increase in cancer growth. Dr. Maurie Markman considers why this occurs and what it means. | 12/12/11 | Free | View In iTunes |
|
45 |
MDV3100: New Variable in Already Complex Equation? | Although new therapies for prostate cancer are always welcome, they further complicate the challenges that clinicians face in advising and managing patients, notes Dr. Gerald Chodak. | 11/30/11 | Free | View In iTunes |
|
46 |
A 'Dirty Bomb' Hits Colorectal Cancer | Dr. John Marshall discusses regorafenib, perifosine, and aflibercept -- 3 promising treatments for refractory colorectal cancer. | 11/10/11 | Free | View In iTunes |
|
47 |
What's Spooky About These Data? | Dr. Bruce Cheson finds it spooky that a well-established investigator publishes a letter in NEJM questioning data from a previously published study in which he was the senior author. | 11/10/11 | Free | View In iTunes |
|
48 |
Cancer Survivorship | Children who have survived cancer are the largest group of survivors. Yet, they are the most vulnerable of this population. Dr. Maris discusses their unique healthcare needs. | 11/7/11 | Free | View In iTunes |
|
49 |
The Problem With Drug Shortages | How is the FDA responding to actual and potential drug shortages? | 11/3/11 | Free | View In iTunes |
|
50 |
When Therapies Are Ineffective | Dr. Kathy Miller discusses the negative data on lapatinib from the ALTTO trial in HER2-positive breast cancer and questions how best to share information with patients on ineffective therapies. | 10/31/11 | Free | View In iTunes |
| Total: 50 Episodes |
